Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.
AVMX-110 is under development for the treatment of wet age-related macular degeneration (wAMD) and polypoidal choroidal vasculopathy (PCV). The drug candidate comprises a recombinant adeno-associated ...
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
It is caused by abnormal blood vessel growth (a condition referred to as 'wet' macular degeneration) or atrophy and accumulation of debris ('dry' macular degeneration), both of which damage the ...
Lifestyle changes can't treat wet age-related macular degeneration (AMD), but might slow its progress. A healthy lifestyle will help you feel better, too.